比较肝硬化与其他常见慢性疾病的费用:基于大型全国保险数据库的纵向研究
该纵向研究利用2011至2020年大型全国保险数据库,识别93,308例肝硬化、355,520例心力衰竭和318,949例慢性阻塞性肺疾病患者,按患者每月计算费用。肝硬化每月总费用3032.00美元,分别比心力衰竭高540.40美元(21.7%)和比慢性阻塞性肺疾病高1076.30美元(55.0%)。失代偿期肝硬化每月费用3969.30美元,分别比心力衰竭高59.3%(1477.70美元)和比慢性阻塞性肺疾病高103.0%(1955.60美元)。
要点
- 肝硬化每月总费用3032.00美元,比心力衰竭高21.7%、比慢性阻塞性肺疾病高55.0%。
- 失代偿期肝硬化每月费用3969.30美元,比心力衰竭高59.3%、比慢性阻塞性肺疾病高103.0%。
- 肝硬化最常见病因是代谢功能障碍相关脂肪性肝炎(37.7%)和酒精相关性肝硬化(22.1%)。
核心结论
- 肝硬化医疗费用高,显著高于心力衰竭和慢性阻塞性肺疾病。
- 针对优化治疗以预防进展为肝硬化和失代偿的干预措施可能减轻这一公共卫生负担。
研究设计与样本
- 纵向研究,利用2011至2020年大型全国保险数据库中的Medicare Advantage参保患者。
- 通过ICD-9/-10代码识别肝硬化、心力衰竭和慢性阻塞性肺疾病患者。
- 共分析93,308例肝硬化、355,520例心力衰竭和318,949例慢性阻塞性肺疾病患者。
- 费用按患者每月计算,包括住院医疗、急诊医疗、药房和其他费用。
主要发现
- 肝硬化、心力衰竭和慢性阻塞性肺疾病患者的平均(标准差)年龄分别为69.6(9.5)、75.9(9.7)和72.9(9.8)岁。
- 肝硬化最常见病因是代谢功能障碍相关脂肪性肝炎(37.7%)和酒精相关性肝硬化(22.1%)。
- 肝硬化、心力衰竭和慢性阻塞性肺疾病每月总费用分别为3032.00、2491.60和1955.60美元。
- 肝硬化费用比心力衰竭高540.40美元(高21.7%),比慢性阻塞性肺疾病高1076.30美元(高55.0%)。
- 失代偿期肝硬化每月费用3969.30美元,比心力衰竭高59.3%(1477.70美元),比慢性阻塞性肺疾病高103.0%(1955.60美元)。
关键数值与推荐
- 肝硬化每月总费用3032.00美元,比心力衰竭(2491.60美元)高540.40美元(21.7%),比慢性阻塞性肺疾病(1955.60美元)高1076.30美元(55.0%)。
- 失代偿期肝硬化每月费用3969.30美元,比心力衰竭高1477.70美元(59.3%),比慢性阻塞性肺疾病高1955.60美元(103.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Cirrhosis prevalence is increasing, yet costs associated with its chronic, complex care are poorly understood. The aim was to characterize the costs of care for patients with cirrhosis and compare them to other chronic diseases such as heart failure (HF) and chronic obstructive pulmonary disease (COPD), for which the public health burden is better recognized. APPROACH AND RESULTS: Patients enrolled in Medicare Advantage plans from a large national insurer between 2011 and 2020 with cirrhosis, HF, and COPD were identified by ICD-9/-10 codes. Costs (USD) of care were calculated per patient-month and included inpatient medical, emergency medical, pharmacy, and other costs. In all, 93,308 patients with cirrhosis, 355,520 patients with HF, and 318,949 patients with COPD were analyzed. Patients with cirrhosis, HF, and COPD had a mean (SD) age of 69.6 (9.5), 75.9 (9.7), and 72.9 (9.8) years, respectively. The most frequent etiologies were metabolic dysfunction-associated steatohepatitis (37.7%) and alcohol-associated cirrhosis (22.1%). The total monthly cost of care for patients with cirrhosis, HF, and COPD was $3032.00, $2491.60, and $1955.60 respectively. The cost for patients with cirrhosis exceeded that for HF by $540.40 (21.7% higher) and COPD by $1076.30 (55.0% higher). The monthly cost of care for decompensated cirrhosis was $3969.30, which was 59.3% ($1477.70) higher than for HF and 103.0% ($1,955.60) higher than for COPD. CONCLUSIONS: The cost of care for cirrhosis is high, significantly higher than HF and COPD. Interventions directed at optimizing care to prevent progression to cirrhosis and decompensation are likely to alleviate this public health burden.
引用
- Obradović F, Vitello DJ, Hasjim BJ, et al. Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database. Hepatology. 2025. PMID: 39773884. doi:10.1097/HEP.0000000000001206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。